Courtney Tate

Courtney Tate

Auto-generated profile, based on publicly available information

Courtney Tate

Pathology Queensland, Princess Alexandra Hospital, Brisbane, Qld, Australia; Department of Haematology, Princess Alexandra Hospital, Brisbane, Qld, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Trends in Immunology
Verified
Journal Article
Closed access
GCGeorgina Clark
Georgina Clark
XJXinsheng Ju
Xinsheng Ju
CTCourtney Tate
Courtney Tate
DHDerek N.J. Hart
Derek N.J. Hart

1 September 2009 in Immunobiology
Verified
Journal Article
Closed access
GCGeorgina Clark
Georgina Clark
XJXinsheng Ju
Xinsheng Ju
MAMaryam Azlan
Maryam Azlan
CTCourtney Tate
Courtney Tate
YDYitian Ding
Yitian Ding
DHDerek N.J. Hart
Derek N.J. Hart

30 August 2019 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
ZAZaid S. Ardalan
Zaid S. Ardalan
SCSujievvan Chandran
Sujievvan Chandran
AVAbhinav Vasudevan
Abhinav Vasudevan
PAPeter W. Angus
Peter W. Angus
AGAndrew Grigg
Andrew Grigg
PGPaul J. Gow
Paul J. Gow
Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage liver disease. We used the Australian Transplant Registry to identify 5 patients referred for liver transplantation between 2008 and 2017. A total of 4 patients had EPP secondary to ferrochelatase deficiency, and 1 patient had X‐linked EPP. No patient had follow‐up with a specialist prior to the diagnosis of progressive liver disease. There were 3 patients who underwent orthotopic liver transplantation, whereas 2 died while on the transplant waiting list. Parenteral PPIX‐lowering therapy was used in 4 patients and was effective in 3 patients, although 2 of these had rebound porphyria and worsening liver function following a decrease in the intensity of therapy. Early disease recurrence in the allograft following transplantation occurred in 2 patients requiring red cell exchange (RCE) to successfully attain and maintain low PPIX levels, but RCE was associated with hemosiderosis in 1 patient. Allogeneic stem cell transplantation (AlloSCT) was performed in 2 patients. One failed engraftment twice, whereas the second rejected the first graft but achieved full donor chimerism with a second graft and increased immunosuppression. In conclusion, our observations suggest that progressive liver disease needs parenteral PPIX‐lowering treatment with the intensity adjusted to achieve a target Erc‐PPIX level. Because EPP liver disease is universally recurrent, AlloSCT should be considered in all patients with adequate immunosuppression to facilitate engraftment. RCE appears to be effective for recurrent EPP liver disease but is associated with an increased risk of iron overload.

1 April 2021 in Pathology
Verified
Journal Article
Closed access
DRDavid Morrall Ross
David Morrall Ross
CTCandice Thomson
Candice Thomson
NHNada Hamad
Nada Hamad
SLSteven W. Lane
Steven W. Lane
KMKate Manos
Kate Manos
PBPiers Blombery
Piers Blombery

1 May 2018 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
APAshvind Prabahran
Ashvind Prabahran
MTMark Tacey
Mark Tacey
SFShaun Fleming
Shaun Fleming
AWAndrew Wei
Andrew Wei
CTCourtney Tate
Courtney Tate
LCLynette Chee
Lynette Chee

6 April 2015 in Medical Journal of Australia
Verified
Journal Article
Closed access
CTCourtney Tate
Courtney Tate
PMPeter Mollee
Peter Mollee
Conservative management avoids the morbidity and costs associated with plasma exchange